William Blair Weighs in on Achaogen, Inc.’s Q4 2017 Earnings (AKAO)
Achaogen, Inc. (NASDAQ:AKAO) – Investment analysts at William Blair dropped their Q4 2017 EPS estimates for Achaogen in a report released on Thursday. William Blair analyst Y. Xu now expects that the biopharmaceutical company will earn ($0.72) per share for the quarter, down from their prior estimate of ($0.66). William Blair also issued estimates for Achaogen’s Q1 2018 earnings at ($0.73) EPS, Q2 2018 earnings at ($0.75) EPS, Q3 2018 earnings at ($0.70) EPS, Q4 2018 earnings at ($0.61) EPS and FY2018 earnings at ($2.78) EPS.
Achaogen (NASDAQ:AKAO) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.13). Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. The company had revenue of $0.58 million during the quarter, compared to analyst estimates of $2.09 million. During the same period in the previous year, the company posted ($0.41) earnings per share. The company’s quarterly revenue was down 96.4% on a year-over-year basis. TRADEMARK VIOLATION NOTICE: “William Blair Weighs in on Achaogen, Inc.’s Q4 2017 Earnings (AKAO)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/william-blair-weighs-in-on-achaogen-inc-s-q4-2017-earnings-akao/1699345.html.
Other equities analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Achaogen in a report on Thursday. Stifel Nicolaus dropped their target price on Achaogen from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday. Mizuho reissued a “buy” rating and issued a $28.00 target price on shares of Achaogen in a report on Thursday. BidaskClub cut Achaogen from a “sell” rating to a “strong sell” rating in a report on Saturday, August 12th. Finally, Guggenheim began coverage on Achaogen in a report on Tuesday, October 24th. They issued a “buy” rating and a $17.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $25.78.
Achaogen (AKAO) opened at $13.29 on Monday. Achaogen has a twelve month low of $4.26 and a twelve month high of $27.79. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 6.99.
In related news, COO Blake Wise sold 3,576 shares of the firm’s stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $15.99, for a total transaction of $57,180.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 8.36% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in AKAO. Bank of New York Mellon Corp increased its holdings in Achaogen by 2.8% during the 1st quarter. Bank of New York Mellon Corp now owns 113,783 shares of the biopharmaceutical company’s stock valued at $2,871,000 after purchasing an additional 3,150 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in Achaogen by 119.1% during the 1st quarter. Parametric Portfolio Associates LLC now owns 51,359 shares of the biopharmaceutical company’s stock valued at $1,296,000 after purchasing an additional 27,914 shares in the last quarter. Vanguard Group Inc. increased its holdings in Achaogen by 11.2% during the 1st quarter. Vanguard Group Inc. now owns 1,066,701 shares of the biopharmaceutical company’s stock valued at $26,913,000 after purchasing an additional 107,406 shares in the last quarter. Geode Capital Management LLC increased its holdings in Achaogen by 18.6% during the 1st quarter. Geode Capital Management LLC now owns 166,055 shares of the biopharmaceutical company’s stock valued at $4,189,000 after purchasing an additional 26,100 shares in the last quarter. Finally, UBS Group AG increased its holdings in Achaogen by 1,183.2% during the 1st quarter. UBS Group AG now owns 45,488 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 41,943 shares in the last quarter. 83.81% of the stock is owned by hedge funds and other institutional investors.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.